StreetAlpha.app
Home › Stocks › MMED

MiniMed Group, Inc. (MMED)

Healthcare
$17.78
▼ −4.66%
LAST CLOSE · NOV 17

MiniMed makes insulin pumps, smart insulin pens, and glucose sensors for people with diabetes. It last closed at $17.78 on Nov 17, down 4.66% on the day. MMED reports earnings on Wed, Dec 30, 2026. The average 12-month price target from 10 analysts is $25.70 (+44.5% from the last close), with a high of $29.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (8 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in MMED, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $3.9M, the largest $1.8M.

AI Auto Pilots
Is MMED in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.2B
Net income
−$314.0M
−9.7% margin
EPS (diluted)
−$1.22
Free cash flow
−$316.0M
−9.8% margin
Valuation
Market cap
$5.0B
281.3M shares
P/E
–
No P/E while losing money
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$207.0M
At Jul 31
Shareholder equity
$3.6B
Shares outstanding
281.3M
At Sep 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $2.5B$2.5BFY2024FY2025: $2.7B$2.7BFY2025FY2026: $3.1B$3.1BFY2026

From MMED's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 8). Last 12 months adds up the four latest quarters.

Next report
Dec 30
2026 · Time not announced
Consensus EPS forecast
$0.12
$825.2M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
8 Buy2 Hold0 Sell
Each firm's latest rating on MMED in the past 90 days
Average 12-month target
$25.70
▲ 44.5% upside

Based on 10 analysts who set a price target on MMED in the past 90 days. The average target is $25.70, with a high of $29.00 and a low of $20.00, compared with the last close of $17.78.

$16$21$25$30PAST 18 TRADING DAYS12-MONTH TARGETSHIGH $29AVG $25.70LOW $20Sep 10LAST CLOSE+12 MO$16$21$25$30PAST 18 DAYSTARGETSHIGH $29AVG $25.70LOW $20Sep 10LAST CLOSE+12 MO
Highest target$29.00
Average target$25.70
Lowest target$20.00
Latest rating changes
BarclaysTarget lowered
Nov 13Hold$22 → $20
JefferiesInitiated
Oct 12Hold$22
MizuhoTarget raised
Oct 8Buy$26 → $28
BarclaysInitiated
Oct 7Hold$22
Truist SecuritiesInitiated
Sep 24Buy$29
DateFirmActionRatingPrice target
Nov 13BarclaysTarget loweredHold$22 → $20
Oct 12JefferiesInitiatedHold$22
Oct 8MizuhoTarget raisedBuy$26 → $28
Oct 7BarclaysInitiatedHold$22
Sep 24Truist SecuritiesInitiatedBuy$29
Loading…

Technical Analysis

MMED · as of the Nov 17 close · updated after every close
Falling

The stock is 3% below its 20 day and 9% below its 50 day average. Momentum is neutral (RSI 46). The nearest support is the Pivot S1 at $17.48, and the nearest resistance the Pivot at $18.04.

Short trendBearish
Long trendNot enough history
MomentumNeutral
StretchNormal
VolatilityNormal, 5.4%/day
Key levels
$24.4352 week high+37.4%
$19.55Swing high (Oct 29)+10.0%
$19.4050 day average+9.1%
$18.89100 day average+6.2%
$18.34Pivot R1+3.1%
$18.3220 day average+3.0%
$18.04Pivot+1.5%
$17.78Last close
$17.48Pivot S1−1.7%
$16.66Swing low (Nov 6)−6.3%
$10.6552 week low−40.1%
Indicators
RSI (14)45.53Middle of its rangeNeutral
MACD-0.32Above its signal lineBullish
Stochastic45.4Middle of its rangeNeutral
ADX (14)23.9Weak trend
Williams %R-65.6Oversold below −80, overbought above −20Neutral
CCI (20)-37.7Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$0.96Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for MMED

What happened before

See how MMED did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 14 – Oct 14
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$3.9M
Largest print
$1.8M
Loading…

MMED Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲114 buying vs 34 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +51
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding14998+52.0%
In funds' top 1030–
Held by funds20.7%13.2%+7.5 pts
New / increased68 / 4653 / 21+54.1%
Reduced / sold out16 / 1813 / 13+30.8%
Put/call ratio1.06––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MMED institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MMED is in one of them and how their past MMED trades turned out.

MMED in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MMED in an article yet. Here's the latest on the wider market.

About MiniMed Group

MiniMed is a medical technology company based in Northridge, California, that develops, manufactures, and sells products for managing diabetes. Its main offerings include automated insulin delivery systems that pair an insulin pump with a glucose sensor and dosing software, along with smart insulin pens and continuous glucose monitoring sensors. Its customers are people with diabetes who need intensive insulin therapy, along with their caregivers and healthcare providers. The company also sells consumable supplies, software, and related services.

Headquarters
Northridge, CA